NeuroNOS
Tel Aviv, Israel· Est.
Israeli biotech targeting ASD core symptoms via nNOS inhibition to reduce nitrosative stress.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech targeting ASD core symptoms via nNOS inhibition to reduce nitrosative stress.
NeurologyNeurodevelopmental Disorders
Technology Platform
Selective inhibition of neuronal nitric oxide synthase (nNOS) to reduce nitrosative stress and restore synaptic function in the brain.
Opportunities
Large unmet need for disease‑modifying ASD therapies and a novel nNOS inhibition mechanism could enable rapid market entry if clinical success is demonstrated.
Risk Factors
Preclinical stage carries translational uncertainty, significant capital requirements, and regulatory challenges inherent to CNS drug development.
Competitive Landscape
Few companies target core ASD symptoms; NeuroNOS differentiates through its focus on nitrosative stress and nNOS inhibition, a mechanism not pursued by major pharma pipelines.